Similarly, individuals with PRKN (MIM: 602544), ATXN2 (MIM: 601517), ATXN3 (MIM: 607047), and MAPT (frontal-temporal dementia [MIM: 157140]) mutations have been reported to have levodopa-responsive clinical PD. The gene discussed is MAPT; the disease is Parkinson disease.